to decades with free-iron toxicity to the underlying tissues. 3 Although the estimated prevalence of SS is approximately 1 in 10 million, the natural history of the condition for those few patients is a progressive decline in neurological function with no known treatments. 4 We investigated the potential for an iron chelator, deferiprone, for the treatment of SS. [5] [6] [7] [8] Deferiprone is the only iron chelator that readily crosses the blood-brain barrier to potentially chelate iron within the central nervous system. 9 Previously, we demonstrated the safety of a 3-month course of deferiprone in a 10-subject open-label pilot trial. 10 Interestingly, four of the 10 subjects in that study demonstrated a slight reduction in hemosiderin deposition by MRI. We sought to investigate the potential benefit of deferiprone by MRI by conducting a 38-subject real-world observational study of SS patients on deferiprone for 2 years to see whether hemosiderosis could be reduced in a safe and tolerable manner.
| METHODS
This was a 2-year longitudinal observational study of 38 subjects Paired t-tests were calculated to determine whether the changes in the whole brain iron content over the 2-year observational period were significant defined by P values < 0.05.
Informed consent was obtained from each subject participating in the study, which was approved by the Johns Hopkins University Institutional Review Board.
| RESULTS
Forty-eight subjects were initially recruited to the study, of which 38 enrolled. The primary reason for exclusion was inability to acquire the drug due to declined coverage by insurance for off-label use. The average age of the group was 64 years old (range 37-86), 53% were male and 94% were white; the full demographics are listed in Table 1 . Among the known etiologies of SS, dural tear was the most common cause but a large number of subjects with unknown bleeding sources despite imaging workup. Eight subjects underwent procedures to correct the bleed although it can be difficult to ascertain whether the bleeding continued, slowed or was stopped in these subjects.
F I G U R E 1 Consort diagram of the participants. Forty-eight participants enrolled in the trial but 10 withdrew, most commonly because of inability to access/afford the deferiprone. A total of 38 participants completed the study
| Clinical
The most common clinical complaints on presentation were hearing loss and imbalance, followed by bowel/bladder dysfunction and symptomatic nystagmus. On examination, hearing impairment was present in 100% of patients and ataxia was found in 95% of patients. Posttreatment clinical data were obtained from 31 of 38 subjects. After 2 years of deferiprone chelation therapy, 19 of 30 (63%) reported no progression or an improvement in at least one neurological domain.
The other 11 (37%) reported a slowly progressive worsening in all clinical domains similar to the progression experienced prior to starting the therapy; however, most patients reported mixed results with worsening in some neurological domains and stabilization in others (Table 2 ). Overall, 40% of patients reported a stabilization in hearing function, 30% reported stable or improved coordination and walking.
There was no indication that the eight subjects who underwent a procedure to stop the bleeding had better outcomes. Of those eight, only one reported stabilization or improvement in clinical function. The most common side effect was fatigue reported by 27% of subjects. The fatigue was dose dependent with a reduction in the morning dose leading to the greatest reduction of the side effect experienced during the day.
| Serology and Hematology
Given the anticipated 1%-2% risk of agranulocytosis associated with deferiprone, all subjects were asked to obtain weekly complete blood counts with differentials to monitor neutrophil counts. While there were no episodes of agranulocytosis among the 38 subjects in this study, two subjects (5%) had episodes of neutropenia to a minimum absolute neutrophil count of 900 cells/μl and were asked to stop taking the deferiprone out of abundance of caution (Table 3) . In both cases, neutrophil counts rebounded within 4 weeks and subjects resumed using deferiprone. There was a slight cumulative decline in total WBC count and neutrophil count over the course of the trial that was statistically significantly but not clinically meaningful ( Figure   S1A -B).
Liver function tests remained within 4 × normal limits in all subjects ( Figure S1C-D) . Ferritin levels consistently declined over time in all subjects as expected in compliant patients ( Figure S1E ). As deferiprone is also a weak zinc chelator, zinc levels were monitored monthly. In five subjects, mild zinc deficiency was noted by blood testing but none of these subjects endorsed symptoms of zinc deficiency ( Figure S1F ). For zinc deficiency, subjects stopped using deferiprone for 2 weeks while taking 20-40 mg of daily zinc tablets. In all cases, zinc levels returned to baseline levels and deferiprone was resumed.
| Radiography
All subjects obtained noncontrast MRI scans of the brain, upon which the diagnosis of SS was made, within 6 months of starting deferiprone. Repeat scans after the completion of the 2-year observational period were obtained in all subjects, but as this was only an observational study, all scans were obtained for clinical use. A comparison of the prestudy and poststudy MRI parameters were performed to identify pairs of scans with the same echo time and the same captured brain volume and found that 16 subjects met these criteria (Table   S1 ). Among these 16 subjects, eight (50%) showed a decrease in the total iron content of the brain by MRI after 2 years of deferiprone use (Table 4 ). In this group of "responders," the average decrease in total iron content was 5% with a range of 1%-13%. In the 50% of subjects who showed an increased total iron content, the increase was 36% with a range of 2%-116%. A sub-analysis of the MRI "responders" shows that 63% were male with an average age of 66 years. We did not have enough participants to assess for an increased chance of responding to deferiprone among those with a history of intervention to stop the bleeding. Clinically, all but one (88%) of the subjects who responded by MRI reported improvement in symptoms in at least neurological domain. The one exception was the subject who improved the least by MRI. Even among the subjects with increasing iron deposits by MRI despite deferiprone, only 38% reported no improvement in any neurological domain. An example MRI for a responder is shown in Figure 2 .
| DISCUSSION
In this longitudinal observational study of a relatively large cohort of patients with superficial siderosis, we report on the potential benefit of long-term iron chelation with the cell-permeable chelator, deferiprone. Despite the significant biases and limits inherent in an observational study, this one provides two important conclusions. First, iron chelation in superficial siderosis appears to lead to reduction in iron deposits over time in more than half of subjects. In our previous open label with deferiprone in superficial siderosis, minor MRI were visible in four of 10 subjects in as little as 3 months, 10 with more obvious MRI changes over longer periods of time. There was no long-standing toxicity or development of agranulocytosis in this 2-year study. In previous studies, a 1%-2% risk of agranulocytosis has been reported. 12 Although none of the subjects in this study developed agranulocytosis, two subjects were found to 
T A B L E 4 MRI changes and clinical correlation
have a decline in neutrophils counts that prompted discontinuation of deferiprone until the counts returned to baseline. In both cases, the neutrophil counts rebounded on discontinuation. Deferiprone was not rechallenged upon resolution of those events out of abundance of caution. In previously reported experience with deferiprone, 10 patients with neutropenia were rechallenged upon recovery of the neutrophil count whereupon only one patient experienced agranulocytosis and no neutropenia or agranulocytosis were observed in the other nine.
12
One trial evaluated if mild neutropenia would necessarily proceed to agranulocytosis with continued deferiprone exposure. Deferiprone was maintained in seven consecutive patients who experienced mild neutropenia and all seven patients normalized their neutrophil counts despite continued deferiprone use. 13 Fatigue was a common complaint among patients on deferiprone in this study and is similar to reported rates of fatigue in other patient populations.
14 Fatigue appeared to be dose dependent in this patient population and was mitigated by dose reductions especially in the morning dose. In most cases, reducing the dose from 1000 mg in the morning to 500 mg in the morning greatly improved the fatigue.
In some cases, the morning dose was added to the evening dose or eliminated altogether.
The potential benefit of deferiprone in superficial siderosis patients is based on the rationale that removing the iron deposits from the brain may lead to healing and improvement in neurological func- F I G U R E 2 Example of MRI susceptibility weighted images from subject 7 (Table 4 ) before starting on deferiprone (A) compared to the same axial cut after 2 years of deferiprone (B). The hypointense dark areas identified by the arrows represent artifact from hemosiderosis, which are grossly reduced after deferiprone use (A) (B)
